Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

141. Understanding why aspirin prevents cancer and why consuming very hot beverages and foods increases esophageal cancer risk. Controlling the division rates of stem cells is an important strategy to prevent cancer (Full text)

Understanding why aspirin prevents cancer and why consuming very hot beverages and foods increases esophageal cancer risk. Controlling the division rates of stem cells is an important strategy to prevent cancer Cancer is, in essence, a stem cell disease. The main biological cause of cancer is that stem cells acquire DNA alterations during cell division. The more stem cell divisions a tissue accumulates over a lifetime, the higher is the risk of cancer in that tissue. This explains why cancer (...) is diagnosed millions of times more often in some tissues than in others, and why cancer incidence increases so dramatically with age. It may also explain why taking a daily low-dose aspirin for several years reduces the risk of developing and dying from cancer. Since aspirin use reduces PGE2 levels and PGE2 fuels stem cell proliferation, aspirin may prevent cancer by restricting the division rates of stem cells. The stem cell division model of cancer may also explain why regular consumption of very hot

2015 Oncoscience PubMed

142. Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial. (Full text)

Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial. The occurrence of new-onset migraine attacks is a complication of transcatheter atrial septal defect (ASD) closure. It has been suggested that clopidogrel may reduce migraine attacks after ASD closure.To assess the efficacy of clopidogrel, used in addition to taking aspirin, for the prevention of migraine attacks following ASD (...) closure.Randomized, double-blind clinical trial performed in 6 university hospitals in Canada. Participants were 171 patients with an indication for ASD closure and no history of migraine.Patients were randomized (1:1) to receive dual antiplatelet therapy (aspirin + clopidogrel [the clopidogrel group], n = 84) vs single antiplatelet therapy (aspirin + placebo [the placebo group], n = 87) for 3 months following transcatheter ASD closure. The first patient was enrolled in December 2008, and the last follow-up

2015 JAMA PubMed

143. Another good reason to recommend low-dose aspirin

Another good reason to recommend low-dose aspirin Another good reason to recommend low-dose aspirin Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Another good reason to recommend low-dose aspirin View/ Open Date 2015-05 Format Metadata Abstract Evidence shows that daily low-dose aspirin during pregnancy can safely (...) lower the risk of preeclampsia and other adverse outcomes. Practice changer: Prescribe low-dose aspirin (eg, 81 mg/d) to pregnant women who are at high risk for preeclampsia because it reduces the risk of this complication, as well as preterm birth and intrauterine growth restriction. URI Part of Citation Journal of Family Practice, 64(5) 2015: 301-303. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2015 PURLS

144. Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force

Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin use in adults: cancer, all cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 132. 2015 Authors' objectives We conducted

2015 Health Technology Assessment (HTA) Database.

145. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force

Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 131. 2015 Authors' objectives

2015 Health Technology Assessment (HTA) Database.

146. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis

Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Aspirin use to prevent cardiovascular disease and cancer: a decision analysis Dehmer SP, Maciosek MV, Flottemesch, TJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dehmer SP (...) , Maciosek MV, Flottemesch, TJ. Aspirin use to prevent cardiovascular disease and cancer: a decision analysis. Rockville: Agency for Healthcare Research and Quality (AHRQ). AHRQ Publication No. 15-05229-EF-1. 2015 Authors' objectives To assess the net balance of benefits and harms from routine use of aspirin for primary prevention across clinically relevant age, sex, and cardiovascular disease (CVD) risk groups. Authors' conclusions Benefits are predicted to exceed harms among persons aged 40-69

2015 Health Technology Assessment (HTA) Database.

147. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force

Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 133. 2015 Authors' objectives We conducted

2015 Health Technology Assessment (HTA) Database.

148. Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy (Full text)

Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA.Participants were assessed at 90 days for functional outcome using the modified Rankin Scale (mRS) and quality (...) of life using the EuroQol-5 Dimension (EQ-5D). Poor functional outcome was defined as mRS score of 2-6 at 90 days and poor quality of life as EQ-5D index score of 0.5 or less.Poor functional outcome occurred in 254 patients (9.9%) in the clopidogrel-aspirin group, as compared with 299 (11.6%) in the aspirin group (p = 0.046). Poor quality of life occurred in 142 (5.5%) in the clopidogrel-aspirin group and in 175 (6.8%) in the aspirin group (p = 0.06). Disabling stroke at 90 days occurred in 166 (6.5

2015 EvidenceUpdates PubMed

149. Another good reason to recommend low-dose aspirin

Another good reason to recommend low-dose aspirin Another good reason to recommend low-dose aspirin Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Another good reason to recommend low-dose aspirin View/ Open Date 2015-05 Format Metadata Abstract Evidence shows that daily low-dose aspirin during pregnancy can safely (...) lower the risk of preeclampsia and other adverse outcomes. Practice changer: Prescribe low-dose aspirin (eg, 81 mg/d) to pregnant women who are at high risk for preeclampsia because it reduces the risk of this complication, as well as preterm birth and intrauterine growth restriction. URI Part of Citation Journal of Family Practice, 64(5) 2015: 301-303. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2015 PURLS

150. Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. (PubMed)

Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. A recent comprehensive review concluded that additional research is needed to determine the optimal use of aspirin for cancer prevention.To assess associations between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk.Population-based, case-control study.Northern Denmark.Patients with first-time colorectal (...) cancer in northern Denmark between 1994 and 2011. Population control participants were selected by risk set sampling.Data on drug use, comorbid conditions, and history of colonoscopy were obtained from prescription and patient registries. Use of low-dose aspirin (75 to 150 mg) and nonaspirin NSAIDs was defined according to type, estimated dose, duration, and consistency of use.Among 10 280 case patients and 102 800 control participants, the adjusted odds ratios (ORs) for colorectal cancer associated

2015 Annals of Internal Medicine

151. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin (Full text)

Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (...) (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. Proportional hazards models were used to test whether each score predicted major bleeding, and comparison of different risk scores was performed using Harell C-statistic and net reclassification improvement index. For the warfarin arm, both scores predicted bleeding risk

2015 EvidenceUpdates PubMed

152. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes (Full text)

Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial (...) termination. We report the 1-year follow-up outcomes of this trial.The trial was a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China. We randomly assigned 5170 patients within 24 hours after onset of minor stroke or high-risk transient ischemic attack to clopidogrel-aspirin therapy (loading dose of 300 mg of clopidogrel on day 1, followed by 75 mg of clopidogrel per day for 90 days, plus 75 mg of aspirin per day for the first 21 days) or to the aspirin-alone group (75 mg

2015 EvidenceUpdates PubMed

153. The prognostic utility of tests of platelet function for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation

The prognostic utility of tests of platelet function for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation The prognostic and diagnostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: A systematic review and economic evaluation Journals Library An error occurred retrieving content to display (...) , please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic

2015 NIHR HTA programme

154. Preoperative Continuation of Aspirin with Appropriate Hemostatic Measures Is Currently Recommended.

Preoperative Continuation of Aspirin with Appropriate Hemostatic Measures Is Currently Recommended. UTCAT2850, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Preoperative Continuation of Aspirin with Appropriate Hemostatic Measures Is Currently Recommended Clinical Question In patients taking daily aspirin as anticoagulant therapy, is it safe to perform dental surgery without withdrawal of aspirin? Clinical Bottom (...) Line Evidence indicates that appropriate local hemostatic measures are sufficient to control bleeding problems resulting from dental surgery for patients taking daily aspirin. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Zhao/2015 1752 patients in 10 included studies Meta-Analysis Key results The risk of hemorrhage after tooth extraction was higher in the group continuing their aspirin therapy

2015 UTHSCSA Dental School CAT Library

155. Dietary Omega-3 Fatty Acids and Aspirin are Effective as Adjunctive Therapy During Non-Surgical Treatment of Chronic Periodontitis

Dietary Omega-3 Fatty Acids and Aspirin are Effective as Adjunctive Therapy During Non-Surgical Treatment of Chronic Periodontitis UTCAT2871, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dietary Omega-3 Fatty Acids and Aspirin are Effective as Adjunctive Therapy During Non-Surgical Treatment of Chronic Periodontitis Clinical Question In patients with chronic periodontitis, does combined dietary omega-3 fatty acids (...) and aspirin reduce the symptoms of periodontitis when compared to a placebo? Clinical Bottom Line Dietary omega-3 fatty acids and aspirin with or without scaling and root planing have been shown to improve clinical parameters of periodontitis, such as reducing probing depths and increasing clinical attachment, in patients with chronic periodontitis. While more long-term studies with comparison to the gold-standard (scaling and root planing) are needed, this combination of drugs shows potential to arrest

2015 UTHSCSA Dental School CAT Library

156. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. (Full text)

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer.To identify common genetic markers that may confer differential benefit from aspirin or NSAID chemoprevention, we tested gene × environment interactions between regular use of aspirin and/or NSAIDs and single-nucleotide polymorphisms (SNPs) in relation to risk of colorectal (...) cancer.Case-control study using data from 5 case-control and 5 cohort studies initiated between 1976 and 2003 across the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) and matched controls (n=8553) ascertained between 1976 and 2011. Participants were all of European descent.Genome-wide SNP data and information on regular use of aspirin and/or NSAIDs and other risk factors.Colorectal cancer.Regular use of aspirin and/or NSAIDs was associated with lower risk

2015 JAMA PubMed

157. Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Article Text Midwifery Systematic review with meta-analysis Low-dose

2015 Evidence-Based Nursing

158. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia (Full text)

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Free Paul Leeson Statistics from Altmetric.com Commentary on : Henderson JT , Whitlock EP , O'Connor E , et al . Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task

2015 Evidence-Based Medicine (Requires free registration) PubMed

159. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors: A Randomized Clinical Trial. (Full text)

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older With Atherosclerotic Risk Factors: A Randomized Clinical Trial. Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population.To determine whether daily, low-dose aspirin reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors.The Japanese Primary Prevention Project (...) aspirin 100 mg/d or no aspirin in addition to ongoing medications.Composite primary outcome was death from cardiovascular causes (myocardial infarction, stroke, and other cardiovascular causes), nonfatal stroke (ischemic or hemorrhagic, including undefined cerebrovascular events), and nonfatal myocardial infarction. Secondary outcomes included individual end points.The study was terminated early by the data monitoring committee after a median follow-up of 5.02 years (interquartile range, 4.55-5.33

2014 JAMA PubMed

160. Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury: A Randomized Clinical Trial. (Full text)

Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury: A Randomized Clinical Trial. Acute kidney injury, a common complication of surgery, is associated with poor outcomes and high health care costs. Some studies suggest aspirin or clonidine administered during the perioperative period reduces the risk of acute kidney injury; however, these effects are uncertain and each intervention has the potential for harm.To determine whether aspirin compared with placebo, and clonidine (...) compared with placebo, alters the risk of perioperative acute kidney injury.A 2 × 2 factorial randomized, blinded, clinical trial of 6905 patients undergoing noncardiac surgery from 88 centers in 22 countries with consecutive patients enrolled between January 2011 and December 2013.Patients were assigned to take aspirin (200 mg) or placebo 2 to 4 hours before surgery and then aspirin (100 mg) or placebo daily up to 30 days after surgery, and were assigned to take oral clonidine (0.2 mg) or placebo 2

2014 JAMA PubMed